

Commission Implementing Regulation (EU) 2020/2105 of 15 December 2020 renewing the approval of the active substance etoxazole as a candidate for substitution in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011 (Text with EEA relevance)

Article 1	Renewal of the approval of the active substance
Article 2	Amendments to Implementing Regulation (EU) No 540/2011
Article 3	Entry into force and date of application
	Signature

ANNEX I

ANNEX II

The Annex to Commission Implementing Regulation (EU) No 540/2011 is...
in Part A, entry 99 on etoxazole is deleted; in...

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/2105. (See end of Document for details)

- (1) [OJ L 309, 24.11.2009, p. 1.](#)
- (2) Commission Directive 2005/34/EC of 17 May 2005 amending Council Directive 91/414/EEC to include etoxazole and tepraloxydim as active substances ([OJ L 125, 18.5.2005, p. 5.](#))
- (3) Council Directive 91/414/EEC of 15 July 1991 concerning the placing of plant protection products on the market ([OJ L 230, 19.8.1991, p. 1.](#))
- (4) Commission Implementing Regulation (EU) No 540/2011 of 25 May 2011 implementing Regulation (EC) No 1107/2009 of the European Parliament and of the Council as regards the list of approved active substances ([OJ L 153, 11.6.2011, p. 1.](#))
- (5) Commission Implementing Regulation (EU) No 844/2012 of 18 September 2012 setting out the provisions necessary for the implementation of the renewal procedure for active substances, as provided for in Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market ([OJ L 252, 19.9.2012, p. 26.](#))
- (6) *EFSA Journal* 2017;15(10):4988. Available online: www.efsa.europa.eu
- (7) Commission Regulation (EU) 2018/605 of 19 April 2018 amending Annex II to Regulation (EC) No 1107/2009 by setting out scientific criteria for the determination of endocrine disrupting properties ([OJ L 101, 20.4.2018, p. 33.](#))
- (8) Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009; <https://www.efsa.europa.eu/en/efsajournal/pub/5311>.
- (9) Commission Implementing Regulation (EU) 2020/869 of 24 June 2020 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, cyazofamid, dimethomorph, ethephon, etoxazole, famoxadone, fenamiphos, flumioxazine, fluoxastrobin, folpet, formetanate, metribuzin, milbemectin, Paecilomyces lilacinus strain 251, phenmedipham, phosmet, pirimiphos-methyl, propamocarb, prothioconazole and S-metolachlor ([OJ L 201, 25.6.2020, p. 7.](#))

Changes to legislation:

There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/2105.